共 64 条
[1]
Matsuo K(2010)Overcoming platinum resistance in ovarian carcinoma Expert Opin Investig Drugs 19 1339-1354
[2]
Lin YG(2007)Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy Gynecol Obstet Invest 63 1-6
[3]
Roman LD(2011)Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804
[4]
DiSilvestro PA(2011)Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2473-2483
[5]
Fisher M(2007)Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann Oncol 18 716-721
[6]
Pearl ML(2017)The pharmacological costs of second-line treatments for recurrent ovarian cancer Int J Gynecol Cancer. 27 1872-1876
[7]
Ledermann JA(2012)OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2039-2045
[8]
Hackshaw A(2015)Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer Gynecol Oncol 139 10-16
[9]
Kaye S(2016)Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer N Engl J Med 375 2154-2164
[10]
Burger RA(2001)Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312-3322